Typical, later-onset forms of Alzheimer's disease (AD) appear to be influenced by multiple susceptibility loci, combinations of which contribute to the development of this disorder. We previously reported the results of a systematic survey of the human genome for the identification of highly informative DNA polymorphisms (SSTRPs) that target new AD risk genes. In addition to the APOE locus, our survey detected five new candidate susceptibility loci for AD, including D10S1423. An association of the D10S1423 234-bp allele with AD has been reported in three independent samples of AD cases and controls (Boston, Pittsburgh, Bonn). Data from our case-control studies suggest a strong synergistic interaction between the D10S1423 234-bp and APOE E4 risk alleles (234-bp carrier: OR = 2.5, 95% CI = 1.4-4.5; E4 carrier: OR = 8.3, 95% CI = 4.3-15.8; both alleles: OR = 23.1, 95% CI = 5.3-99.5). This report describes the prospective, longitudinal, double-blind assessment of the age-specific risk of AD encountered by 325 asymptomatic first-degree relatives of AD probands who carried the D10S1423 234-bp allele, the APOE E4 allele, or both, after 11.5 years of systematic follow-up. A total of 18 incident cases of AD were detected during the first 3379 subject-years of this longitudinal study. The effects of carrying either or both of the D10S1423 234-bp and APOE E4 alleles on the age-specific risk of developing AD were determined using Kaplan-Meier survival analysis. The age-specific risk of developing AD was the greatest for individuals who carried both alleles (Mantel-Cox statistic = 20.12, df = 3, P = 0.0002; Breslow statistic = 13.36, df = 3, P = 0.004). Cox proportional hazards models were developed to estimate the risk ratios for each genotype, controlling for the potential effects of age at recruitment, sex, and years of education. In the resulting best fitting model, only individuals who carried both risk alleles exhibited a risk ratio that differed significantly from 1 (risk ratio = 16.2, P = 0.008, 95% CI = 2.1-128.3). After controlling for these genotypes, female gender was also significantly associated with increased risk of developing AD (risk ratio = 5.1, P = 0.02, 95% CI = 1.2-21.1). Neither age at recruitment nor years of education made significant contributions to the model. Molecular Psychiatry (2001) 6, 413-419.
Introduction
Alzheimer's disease (AD) is the most common cause of dementia and mental impairment among the elderly. [1] [2] [3] The defining features of AD include progressive, global cognitive impairment that develops in individuals whose brains manifest densities of senile plaques that exceed those expected for age. 4, 5 However, patients with this disorder manifest remarkable inter-individual variability in other clinical characteristics, including age at symptomatic onset; rate and pattern of pro-gression; emergence of disturbances of mood, thought, perception, and behavior; development of extrapyramidal symptoms; and presence of a family history of ADlike dementia. Postmortem and genetic studies have also revealed considerable inter-individual variation in comorbid neuropathologic findings, brain neurochemical abnormalities, and contributions from particular genetic factors. This level of heterogeneity suggests that AD, as currently defined, may more closely resemble a syndrome with multiple contributing etiologies than a disease with a unitary cause. 6 Although they are uncommon, the majority of cases of AD that become symptomatic before the age of 60 appear to arise from highly penetrant, autosomal dominant genetic lesions. These include mutations in the structural genes for the amyloid precursor protein located on chromosome 21, 7,8 presenilin 1 located on chromosome 14, 9-12 presenilin 2 located on chromosome 1, 13, 14 as well as trisomy 21. 15 More typical, lateronset forms of AD appear to be influenced by multiple susceptibility loci, combinations of which contribute to the development of this disorder. One such locus, APOE, is the structural gene for an apolipoprotein involved in lipid transport and metabolism. 16 An association of the APOE E4 allele with late-onset familial and sporadic AD has been observed in many populations throughout the world and is now well established. 17, 18 The known AD susceptibility genes have been estimated to account for only a portion of the heritability of AD, 19 underscoring the importance of continuing the search for additional AD risk loci. With this goal in mind, we conducted a systematic survey of the human genome, conducted at an average resolution of 10 cM, for the identification of highly informative DNA polymorphisms (SSTRPs, simple sequence tandem repeat polymorphisms) that target new AD risk genes or reside in close proximity to such loci by virtue of linkage disequilibrium. 20, 21 In addition to the APOE locus, our survey detected five new candidate susceptibility loci for AD including D10S1423 located at 10p13. These allelic associations were observed in independent samples of autopsied AD cases and controls from geographically disparate sites (Boston and Pittsburgh). In the combined case-control sample of 200 AD cases and controls, the odds ratios for developing AD among carriers of the D101423 234-bp allele or the APOE E4 allele were 2.5 (95% CI = 1.4-4.5) and 8.3 (95% CI = 4.3-15.8), respectively.
The association of the D10S1423 234-bp allele with AD detected by our genome survey has recently been replicated in an ethnically homogeneous group of 397 German AD cases and controls. 22 Their data as well as ours indicate a strong interaction between the risk of AD conferred by the D10S1423 234-bp and APOE E4 alleles. In our combined sample of 200 AD cases and controls the odds ratio for developing AD among individuals who carried both risk alleles rose to 23.1 (95% CI = 5.3-99.5).
Prospective, double-blind, controlled study designs have historically provided the most definitive tests of putative risk factors and experimental treatments for clinical disorders. We embarked on a prospective, longitudinal study of 330 cognitively intact individuals between the ages of 40 and 75 years, who were firstdegree relatives of probands with AD, with the goal of evaluating putative risk factors for this neurodegenerative disorder. 23 Recruitment was restricted to subjects who had no history of cognitive decline or evidence of impairment as determined by clinical, functional, and psychometric assessments, so that risk factors that act at early stages in the pathogenesis of AD could be detected. Subject selection was designed to include individuals who represented a wide age range so that the effects of age-specific risk factors would be observable. By recruiting a cohort of individuals whose overall incidence rate of developing AD would be expected to be several-fold higher than that in a community sample by virtue of their family history, [24] [25] [26] [27] we anticipated that the overall number of subject-years of follow-up required to detect risk factors that had at least moderate-sized effects would be feasible. Transformed cell lines from these individuals were established so that the effects of genetic polymorphisms or mutations that modulate the age-specific risk of developing AD could be evaluated. This report describes a prospective, longitudinal, double-blind assessment of the age-specific risk of AD encountered by asymptomatic firstdegree relatives in this cohort who carried the D10S1423 234-bp allele, the APOE E4 allele, or both, after 11.5 years (3379 subject-years) of systematic follow-up.
Subjects and methods

Recruitment of the AD high-risk cohort
The AD high-risk cohort consisted of 330 first-degree relatives of 189 demented probands who met NINCDS-ADRDA criteria 28 for possible (n = 35), probable (n = 103), or definite (n = 6) AD and/or DSM-III-R criteria 29 for primary degenerative dementia of the Alzheimer's type (n = 45). Members of the cohort were between the ages of 40 and 75 and were cognitively intact at the time of recruitment as determined by a review of medical and psychiatric history, a survey of current activities of daily living, a mental status examination, and the Mini-Mental State Examination (MMSE). 30 Subjects with any clinical evidence of cognitive decline or impairment, or a MMSE score of Ͻ27, were excluded. For 303 of the 330 subjects, the MMSE was augmented by the more detailed Mattis Dementia Rating Scale (MDRS), 31 and all individuals tested had MDRS scores in the range expected for healthy elderly controls (Ն135). All members of the cohort provided written informed consent for participation in this study which was approved by the Biomedical Institutional Review Board of the University of Pittsburgh.
Longitudinal surveillance protocol
Semi-structured telephone assessments were initiated on March 1, 1989, and performed approximately annually by a research nurse with specialized experience in geriatrics who remained blind to the laboratory data. The telephone assessments included a review of the items on the Family History Form of Huff and colleagues 27 and a survey of the subjects' activities of daily living. Subjects and their identified 'best' informants were encouraged to contact the research nurse if any evidence of a change in mental functioning occurred during the interim. To determine the sensitivity and specificity of the telephone assessments for the detection of individuals with newly emergent cognitive impairment, 202 members of the AD high-risk cohort were re-evaluated by in-person interviews. The telephone assessments detected subjects whose Clinical Dementia Rating scores (CDR) 32 exceeded 0 with a sensitivity of 82% and a specificity of 98%. These crosssectional determinations seem likely to underestimate the sensitivity and specificity of the telephone assess-ments for identifying cases of progressive dementia when administered longitudinally over a period of years.
In-person assessments were performed when evidence suggestive of emergent cognitive dysfunction was reported during the telephone screen. If the presence of cognitive impairment suggested by the telephone screen was supported by a MMSE score Ͻ27, a MDRS score Ͻ135, a CDR score Ͼ0, or other clinical evidence obtained during the in-person evaluation, the subject was referred for a complete diagnostic evaluation. If no such evidence was detected, the frequency of the periodic telephone follow-up was increased to approximately every 6 months. Clinical diagnoses of AD among incident cases of dementia were established according to the DSM-III-R criteria and NINCDS-ADRDA criteria, as applied by board-certified specialists with added qualifications in geriatric psychiatry. Autopsies were performed by board-certified neuropathologists and neuropathologic diagnoses were made according to generally accepted criteria. 4, 5, 33 Laboratory methods Venous blood samples were obtained by antecubital phlebotomy by qualified clinical staff who coded the samples prior to transport to the laboratory. Lymphocytes were isolated under sterile conditions by centrifugation on an Histopaque 1077 step gradient according to the manufacturer's instructions (Sigma Chemical, St Louis, MO, USA). Lymphoblast cell lines were established by exposure of lymphocytes to Epstein-Barr virus.
Genotyping of coded samples was performed by laboratory staff who were blind to sociodemographic and clinical information. Genomic DNA was isolated from lymphocytes or lymphoblasts using minor modifications of standard methods. 34, 35 Genotyping of the D10S1423 polymorphism was performed as previously described, 21 using polymerase chain reaction (PCR) methodology employing the oligonucleotide primer pair included in the CHLC Human Screening Set/Weber Version 6 (Research Genetics, Huntsville, AL, USA). Following amplification, the resulting PCR products were resolved by electrophoresis under denaturing conditions, visualized by autoradiography, and sized by comparison to individuals of known genotypes from the CEPH panel, 1331-01 and 1331-02 (Coriell Institute, Camden, NJ, USA). Genotyping of the APOE locus was performed using PCR methodology and the oligonucleotide primers (Gibco BRL, Gaithersburg, MD, USA) described by Hixson and Vernier. 36 The radiolabeled products of each amplification were digested with endonuclease Hha I and the resulting fragments were resolved by electrophoresis under nondenaturing conditions. The labeled restriction fragments were visualized by autoradiography and allele assignments were made as previously described. 37 
Statistical analysis
The database for this project was frozen on September 7, 2000. Continuous variables were compared using the Molecular Psychiatry t statistic. Categorical variables were compared using the 2 statistic or Fisher's exact test, as appropriate. Survival analyses employing the Kaplan-Meier product limit method and Cox proportional hazards models with covariates were performed using SPSS Version 10 (SPSS, Chicago, IL, USA).
Results
A description is presented in Table 1 of the AD high risk cohort and 18 incident cases of AD. The cohort was composed almost entirely of Caucasians and included approximately equal proportions of men and women. The subjects had a mean age of 56.1 years at the time of entry into the longitudinal study and a mean age of 66.6 years at the time of their most recent follow-up assessment (effective Sept 7, 2000; 11.5 yrs of follow-up). On average they had completed a high school education. Consistent with the criteria for entry into the study, all subjects were cognitively intact as reflected by a mean MMSE score approaching 30. As expected, the proportions of individuals in the high risk cohort who carried the D10S1423 234-bp or APOE E4 alleles, 40.0% and 47.5%, were approximately midway between those observed for autopsy-confirmed AD cases and controls reported in our genome survey. 21 A total of 62 of the 189 probands with clinically diagnosed AD were autopsied during the course of this study and the diagnosis was histopathologically confirmed in 60 (96.8%) of these 62 cases. Of the two autopsied cases that did not meet histopathologic criteria for AD, one exhibited striatonigral degeneration and the other exhibited neuronal loss without findings to support a more specific diagnosis. To date, the annual rate of attrition from this longitudinal study has averaged 2.3% and the most common source of attrition has been death.
A total of 22 incident cases of perceived memory impairment were detected by our surveillance protocol during the first 3379 subject-years of this longitudinal study. Eighteen of these cases revealed objective evidence of cognitive impairment and developed progressive dementias that resulted in their inability to function independently. They manifested the onset of cognitive impairment at a mean age of 70.6 ± 6.3 years and the progression of their cognitive impairment has been monitored for an average of 4 years ( Table 1) . In all 18 cases, medical and laboratory evaluations supported the diagnosis of AD. Following the death of one of these cases, for whom concurrent cerebrovascular disease was detected clinically, an autopsy was performed and the diagnosis of AD with multiple infarcts was determined by neuropathologic examination of the brain.
As shown in Table 1 , the 18 incident AD cases were similar to the remaining members of the ADHRC in sex ratio, race, years of education, and cognitive performance on the MMSE at the time of recruitment. The effects of carrying either or both of the D10S1423 234-bp and APOE E4 alleles on the age-specific risk of developing AD were determined using Kaplan-Meier survival analysis. As shown in Figure 1 , the age specific-risk of developing AD was the greatest for individuals who carried both alleles (Mantel-Cox statistic = 20.12, df = 3, P = 0.0002; Breslow statistic = 13.36, df = 3, P = 0.004).
A Cox proportional hazards model was developed to estimate the risk ratios for each genotype, controlling for the potential effects of age at recruitment, sex, and years of education. In the resulting model described in Table 2 , only individuals who carried both risk alleles exhibited a risk ratio that differed significantly from 1 (risk ratio = 16.2, P = 0.008, 95% CI = 2.1-128.3). Interestingly, female gender was also significantly associated with an increased risk of developing AD (risk ratio = 5.1, P = 0.02, 95% CI = 1.2-21.1). Neither age at recruitment nor years of education made significant contributions to the model. 
Discussion
This report provides evidence from a prospective, longitudinal, double-blind study that the D10S1423 234-bp and APOE E4 alleles confer increased risk of AD among asymptomatic, first-degree relatives of AD probands, an effect that is most pronounced for individuals who carry both alleles (estimated risk ratio = 16.2). The molecular mechanisms that underly these observations may provide new insights into the pathophysiology of this common neurodegenerative disorder. An important next step in this investigation will be to identify the gene in close proximity (a cM or so) to D10S1423 that is responsible for generating the linkage disequilibrium of this SSTRP locus with AD. At least four genes 38 reside within approximately 1 Mb of D10S1423: VIM, the structural gene for vimentin, a major component of intermediate filaments; DNMT2, which encodes DNA (cytosine-5-)-methyltransferase 2; CUBN, which encodes cubilin, an intrinsic factor-cobalamin receptor; and BMI1, which encodes a murine leukemia viral oncogene homologue, 39 all of which have been cytogenetically localized within or adjacent to 10p13. The D10S1423 polymorphism appears to reside an estimated 35 kb distal to BMI1. More precise localization of these loci is not yet possible because continuous nucleotide sequence data in the region of D10S1423 are not yet available in Gen-Bank. 40 In addition to these genes, the structural gene for glycogen synthase kinase 3B, GSK3B, has been mapped by Genethon to within several hundred kb of D10S1423, although other studies localize GSK3B to chromosome 3. 41 All five of these genes are plausible candidates for AD susceptibility loci. Pathological changes in the neuronal cytoskeleton are among the histologic hallmarks of AD, 4, 5, 33 and alterations in intermediate filament proteins such as vimentin may be among these. Mutations in the structural gene for an X-linked DNA methyltransferase, MECP2, produce Rett syndrome which includes prominent central neurological manifestations. 42 Oncogenes are often involved in the control of cell division as well as programmed cell death, and apoptotic events appear to contribute to the process of neuronal death in AD. 43 Apolipoproteins and their receptors appear to play an important role in the metabolism of cholesterol in the brain and in the outcome of neuronal injury. 44, 45 In addition to facilitating the absorption of the intrinsic factor-vitamin B 12 complex, cubilin is a high-affinity apolipoprotein A-I receptor that facilitates the endocytosis of high-density lipoprotein (HDL) holoparticles and their subsequent transport to endosomes/lysosomes where they are digested. 46, 47 This endocytic process resembles that for low-density lipoproteins (LDL) and appears to involve the participation of the co-receptor megalin, a member of the LDL receptor family. [46] [47] [48] Moreover, cubilinmediated HDL endocytosis is inhabitable by apolipoproteins including A-I, A-II, and E. 46 These features provide a biochemical basis for interactions between apolipoproteins, including apolipoprotein E, and cubilin as part of a physiologic process that is likely to be relevant to the neurodegeneration/repair that occurs in AD. Finally, glycogen synthase kinase 3B phosphorylates tau and may contribute to the formation of neurofibrillary tangles in AD through a process that is facilitated by the binding of both proteins to presenilin 1. 49 When controlling for the effects of the D10S1423 and APOE genotypes, female gender was also associated with an increase in the age-specific risk of developing AD. Whether this effect was mediated through one or more additional risk alleles located on the sex chromosomes, hormonal influences, or sex-related environmental exposure(s) cannot be determined from our data. However, it is interesting that the strongest allelic association with AD identified by our genome survey occurred at DXS1047, a SSTRP located at Xq25. 20, 21 Future analyses will evaluate whether DXS1047 contributes to this gender effect.
Three of the five novel candidate risk alleles for AD detected by our genome survey, including D10S1423, appear to modulate cortical levels of the amine neurotransmitters dopamine and norepinephrine in important ways. [50] [51] [52] As a result, their inheritance may influence the development of behavioral disturbances that are common sources of excess morbidity in AD. For example, the emergence of clinically significant depression in the context of primary dementia has been reported to be associated with degeneration of the Molecular Psychiatry dopaminergic neurons in the substantia nigra and noradrenergic neurons in the locus ceruleus. [53] [54] [55] These genotypes may also contribute to the development of psychosis, apathy, and extrapyramidal symptoms, and to inter-individual differences in response to the therapeutic or adverse effects of medications that involve these aminergic systems.
In addition to their relevance to the behavioral manifestations of AD, emerging evidence suggests that these AD susceptibility loci may be shared with psychiatric disorders whose symptomatic onsets occur earlier in life. 56 Three independent groups have reported evidence for linkage of schizophrenia to D10S1423. [57] [58] [59] Evidence for linkage of bipolar disorder 60 and female alcoholism 61, 62 to a susceptibility locus at or near D10S1423 has also been reported. The pathophysiology of all three of these idiopathic disorders appears to include derangements of the aminergic nervous system. It is tempting to speculate that the effect of the D10S1423 genotype (or that of a nearby locus) on the central aminergic phenotypes of patients with AD may also contribute to abnormalities of those neuronal systems in mental disorders that become manifest in early or middle adulthood.
These findings may contribute to advancements in the therapeutics of AD in several important ways. Characterization of the molecular mechanisms that underly the increased risk of AD conferred by the D10S1423 234-bp and APOE E4 alleles, and their synergistic interaction, may provide new molecular targets for therapeutic drug development. Furthermore, the continued elucidation of genetic factors that identify asymptomatic individuals at risk of developing AD will facilitate the design of therapeutic trials involving subjects who have the greatest likelihood of responding and for whom successful interventions would have the greatest impact. Finally, genotypic subtypes of AD may manifest greater pathogenic homogeneity than the syndrome of AD as a whole. As a result, this approach to reducing the variance in disease pathogenesis may be important for the discovery of drugs or other interventions that have beneficial effects on preventing, forestalling the onset, slowing the progression, or ameliorating the symptoms of dementia in some subtypes of AD but not others.
Our ongoing longitudinal study focuses on a cohort of asymptomatic individuals who are at increased risk of developing AD by virtue of their family history. After 3379 subject-years, our surveillance protocol has detected 18 incident cases of AD. This number of incident cases currently limits the statistical power of our study to detect alleles that have more modest effects on susceptibility to AD than the D10S1423 234-bp and APOE E4 alleles. More incident cases would have been detected during this interval by recruiting individuals with mild cognitive impairment or who had lived further into the age of risk. However, it is likely that many individuals with mild cognitive impairment, especially those who carry the APOE E4 allele, are already manifesting early symptoms attributable to AD, the most common form of dementia. In contrast, our goal was to identify risk factors for events that contribute to the pathogenesis of AD at an early time before symptoms emerge. Likewise, the recruitment of an older cohort would have limited our ability to detect risk factors that specifically influence the development of forms of AD that emerge at earlier ages.
Our ADHRC currently has a mean age of 67 and an accelerating incidence rate of AD is evident among its remaining members. As the cohort continues to age, we anticipate that the ADHRC and associated library of transformed cell lines will provide a unique resource for efficiently evaluating putative AD susceptibility alleles that have moderate effects among asymptomatic individuals using the prospective, longitudinal, double-blind study design that we envisioned 15 years ago.
